Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)

Withdrawn

Conditions: hypertension of the lungvessels
in sarcoidosis patiente
pulmonary hypertension
10037454

Registration Number: NL-OMON38714

Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Withdrawn

Sex: Not specified

Target Recruitment: 10

Inclusion Criteria

Patients with sarcoidosis as defined by the ATS/WASOG statement
Patients with pulmonary hypertension as confirmed by right heart catheterization
Patients willing to provide written informed consent

Exclusion Criteria

Unwillingness to provide assurance that they will complete the follow up visits for the study.

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary Objective<br /><br><br /><br>Characterize the demographics, clinical course, hemodynamics, pulmonary<br /><br>physiology, and disease management of sarcoidosis associated pulmonary<br /><br>hypertension on the United States compared to non-US sites.<br /><br><br /><br>Endpoints<br /><br><br /><br>1. Progression of disease to death or transplant<br /><br>2. Hospitalization<br /><br>3. Institution of new therapy for pulmonary hypertension<br /><br>4. Six minute walk distance<br /><br>5. Change in Saint George Respiratory Questionnaire of >4 points</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. Determine what factors are associated with a bad prognosis in patients<br /><br>diagnosed with SAPH<br /><br>2. Determine if there is a difference in survival in patients treated with<br /><br>different management strategies<br /><br>3. Determine the role of immunosuppressive therapy in management of SAPH</p><br>